LCN2 and chronic kidney disease: A recent crossover randomised control trial in diabetic patients with early signs of kidney dysfunction (CKD Stage 2), found that six weeks of treatment of 4 g/day n-3 PUFA led to a reduction of 16% in urinary neutrophil gelatinase-associated lipocalin (NGAL), a marker of kidney dysfunction [164].